UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): April 23, 2018
Universal Biosensors, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 000-52607 | 98-0424072 | ||
| (state or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) | ||
| 1 Corporate Avenue Rowville, 3178, Victoria Australia |
Not Applicable | |||
| (address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: +61 3 9213 9000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers, Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On April 23, 2018, Dr. Alastair Hodges gave notice of his resignation as Chief Scientist of our wholly owned subsidiary, Universal Biosensors Pty Ltd, which will take effect on July 13, 2018. Universal Biosensors Pty Ltd and Dr. Hodges are currently negotiating the terms of a consulting agreement under which Dr. Hodges will provide consulting and advisory services to the Company following the effectiveness of his resignation. The Company thanks Dr. Hodges for his service.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| UNIVERSAL BIOSENSORS, INC. | ||||||
| Date: April 24, 2018 | By: | /s/ Cameron Billingsley | ||||
| Cameron Billingsley | ||||||
| Company Secretary | ||||||